The Healing Power of Botanical Therapeutics®


Herborium Expends Its HUT Group Partnership to Reach £500,000 ($785,000.00) Sales in Europe.

Fort Lee, N.J. December 11th, 2014  Herborium® Group, Inc. (OTC Pink: HBRM),, a Botanical Therapeutics® Company and the provider of unique all  botanical medicines (Botanical Therapeutics®)  announced today that HUT Group, LLC. , the UK’s leading multi-website online retailer of Health and Beauty products is expanding the marketing and sales of AcnEase®, Herborium’s unique acne treatment  on its leading platforms with a goal of  £500,000.00 ($785,000.00) in sales within  next 18-24 months. Hut will also introduce Herborium’ women, men and energy products in the European market in 2015.

The Hut Group is one of Europe's fastest growing online lifestyle and health & and beauty destinations.  It is currently the UK’s leading multi-website online retailer with rapidly growing global operations including a significant growth in Asia. Hut supports more than 140 million global website visitors, 5 million customers and 8 million orders dispatched worldwide across such on line stores as,,,, and others.

“We are very excited about the expansion of marketing and sales of AcnEase® and introduction of other Herborium products on Hut unique end to end technology platform. With potential for a million pageviews daily our Botanical Therapeutics® will reach millions of customers in Europe and Asia.  We are expecting Hut’s goal for £500 thousand in sales of AcnEase®  to be just a beginning of new growth opportunities” commented Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium.


About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements).  The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.  Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women’s health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit, and

Safe Harbor Statement:  This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc. , which involves risks and uncertainties.  The Company's actual future results could materially differ from those discussed.   The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.

Contact Information: Herborium Group, Inc.

Information provided on about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.